University of Wisconsin, Madison

wisc.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

1,166

Active

213

Phase 3

29

Total enrollment

2,560,650

Pipeline matrix

Showing 40 of 93 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Letermovir2
Nicotine patch12
Varenicline7
Paclitaxel4
Fluticasone Propionate1
TAP Anesthesia1
Surgeon-Initiated Local Anesthetic1
Nicotine Pouches1
Mini Nicotine lozenges1
Envarsus XR2
Pembrolizumab6
Nivolumab4
Bevacizumab4
Cetuximab4
pTVG-HP3
pTVG-AR3
Prazosin3
Saline2
18F-fluorofuranylnorprogesterone2
Prednisone3
Tranexamic Acid2
Anastrozole2
Pegfilgrastim3
Doxorubicin3
Vincristine2
Degarelix2
Oxaliplatin2
GM-CSF2
Panitumumab2
Celecoxib2
FAPI tracer1
CBD1
18F-DCFPyL1
Rifampicin1
Isoniazid1
Pyrazinamide1
Ethambutol1
Cemiplimab1
Fianlimab1
FLT PET/CT1
53 more active programs hidden

Next readouts

  • 2022-11-07
  • 2023-12
  • 2024-04-18
  • 2024-11-24
  • 2025-01-13
  • 2025-12-09
  • 2026-04-02
  • 2026-07
  • 2026-08
  • 2026-08

Top conditions

  • Breast Cancer33
  • Prostate Cancer31
  • Healthy27
  • Obesity27
  • Smoking26
  • Smoking Cessation26
  • Nicotine Dependence20
  • Asthma19

Frequently asked questions about University of Wisconsin, Madison

How many clinical trials does University of Wisconsin, Madison have on ClinicalTrials.gov?
University of Wisconsin, Madison is listed as the lead sponsor on 1,166 clinical trials in ClinicalTrials.gov, 213 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Wisconsin, Madison's trials are in Phase 3?
29 of University of Wisconsin, Madison's trials are in Phase 3, spread across 93 active drug programs.
What therapeutic areas does University of Wisconsin, Madison focus on?
University of Wisconsin, Madison's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Healthy, Obesity, Smoking.
When are University of Wisconsin, Madison's next clinical trial readouts?
University of Wisconsin, Madison has 10 upcoming primary-completion readouts tracked here; the soonest is “pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer”, expected around 2022-11-07.